This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Gonadotrophin-releasing hormone-I and -II stimulate
steroidogenesis in prepubertal murine Leydig cells in vitro
Yung-Ming Lin1, Ming-Yie
Liu2, Song-Ling Poon1,3, Sew-Fen
Leu4, Bu-Miin Huang3
1Department of Urology,
2Department of Environmental and Occupational Health,
3Department of Cell Biology and Anatomy,
College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan, China
4Institute of Bioindustrial Technology, College of Human Ecology, HungKuang University, Taichung 43302, Taiwan,
China
Abstract
Aim: To study the effect and mechanism of gonadotrophin-releasing hormone (GnRH) on murine Leydig cell
steroidogenesis. Methods: Purified murine Leydig cells were treated with GnRH-I and -II agonists, and testosterone
production and steroidogenic enzyme expressions were determined.
Results: GnRH-I and -II agonists significantly
stimulated murine Leydig cell steroidogenesis 60%_80% in a dose- and time-dependent manner
(P < 0.05). The mRNA expressions of steroidogenic acute regulatory (StAR) protein, P450scc,
3β-hydroxysteroid dehydrogenase (HSD), but not 17α-hydroxylase or
17β-HSD, were significantly stimulated by both GnRH agonists with a 1.5- to
3-fold increase (P < 0.05). However, only
3β-HSD protein expression was induced by both GnRH agonists, with a 1.6- to
2-fold increase (P < 0.05).
Conclusion: GnRH directly stimulated murine Leydig cell steroidogenesis by activating
3β-HSD enzyme expression. (Asian J Androl 2008 Nov; 10: 929_936)
Keywords: gonadotrophin-releasing hormone; Leydig cells; murine; steroidogenesis; stimulation
Correspondence to: Dr Bu-Miin Huang, Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University,
#138, Sheng Li Road, Tainan 70101, Taiwan, China.
Tel: +886-2089-357 Fax: +886-2093-007
E-mail: bumiin@mail.ncku.edu.tw
Received 2007-12-19 Accepted 2008-04-20
DOI: 10.1111/j.1745-7262.2008.00434.x
1 Introduction
Gonadotrophin-releasing hormone (GnRH), a decapeptide in the hypothalamus, plays a pivotal role in
regulating reproduction by stimulating the biosynthesis and
release of luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) from the pituitary [1].
Several GnRH molecules have been found in vertebrates and
invertebrates as multiple forms [2]. Up to now, two forms of
GnRH (GnRH-I and GnRH-II) have been demonstrated with distinct functions among various species and
tissues [3]. Studies have illustrated the presence of GnRH
or GnRH-like material in cultured rat Sertoli cells and
testis [4, 5] and the existence of GnRH-R in rat
interstitial cells and testis [5_7]. It has also been well
demonstrated that GnRH-R is expressed in Leydig cells [1],
and the binding activity is present in rat Leydig cells [8].
Thus far, no direct evidence of the existence of GnRH-I
and GnRH-II in the murine testis has been demonstrated.
However, in humans, expression of GnRH-I in Sertoli cells
and GnRH-R in Leydig cells has been shown [3],
indicating that GnRH may function in testicular steroidogenesis.
It is known that short-term in vitro treatment of GnRH
stimulates testosterone production by adult rat Leydig
cells [9], whereas long-term incubation decreases the
response to human chorionic gonadotrophin (hCG) [10].
In addition, GnRH or its agonist induced paradoxical
effects on testosterone secretion in adult
hypophysectomized rats [11] by inhibiting basal and LH-dependent
steroidogenesis in rat fetuses in vivo [12]. Some studies
from various frog species reveal that GnRH agonists or
GnRH-like materials have positive effects on
testosterone production [13]. These observations suggest that
GnRH has direct effects on Leydig cells, and these
effects might be species-specific.
Up to now the cellular responses to the GnRH within
Leydig cells are yet to be determined, and few studies
are available concerning the biological functions of
testicular GnRH in the mouse. Although some reports have
demonstrated the absence of a direct effect and binding
activity of GnRH or GnRH agonists on murine testis and
Leydig cells [14], we now demonstrate that GnRH-I and
GnRH-II agonists significantly stimulate purified murine
Leydig cell testosterone production dose- and
time-dependently. Furthermore, the present study attempts
to determine the mechanism of how GnRH could activate murine Leydig cell steroidogenesis.
2 Materials and methods
2.1 Animals
Male B6 (C57BL/6NCrj) mice, 5_7 weeks old, were
purchased from National Cheng Kung University Animal
Center (Tainan, Taiwan, China). Juvenile B6 mice should
be less than 8 weeks old for the experiment to exclude the
exposure of Leydig cells to endogenous LH. All animals
were housed in groups of four in 29 × 18 × 13 cm
polyethylene cages. The animal room was maintained at
22_24ºC under a constant 12 h:12 h light : dark cycle. Purina
mouse chow (Ralston-Purina, St. Louis, MO, USA) and
water were always available. The procedure for
sacrificing animals was approved by the counselors of the
National Cheng Kung University Animal Center.
2.2 Leydig cell isolation
Testes were removed from cervically dislocated mice
and decapsulated in M199 (Gibco/BRL, Gaithersburg,
MD, USA) (1 L containing 4 mmol/L
NaHCO3, 25 mmol/L HEPES, 0.06 g penicillin, 0.05 g streptomycin and 0.2%
[w/v] bovine serum albumin [BSA], pH 7.35). After
decapsulation, the testes were incubated in a shaking
water-bath (120 cycles/min) at 37ºC in M199 containing
1% [w/v] BSA and 100 U/mL collagenase for 15 min.
After incubation, cold M199 was added to stop the
action of collagenase. Seminiferous tubules were
separated from interstitial cells by gravity sedimentation. Cells
were then collected by centrifugation (300 ×
g for 6 min) and resuspended in 2 mL M199 containing 0.1% [w/v]
BSA. This suspension, which comprised interstitial cells
only, contained 20%_30% Leydig cells. This
interstitial cell preparation was layered onto a Percoll
gradient and then centrifuged at 800 ×
g at 4ºC for 20 min. The gradient, which was performed by centrifugation
at 25 000 × g for 40 min, contained 10 mL
isotonic Percoll solution (40%) and 15 mL M199 plus
0.1% [w/v] BSA and 25 mmol/L HEPES. A 1 mL fraction of gradient was
collected from the top. Murine Leydig cells were mainly
distributed in fractions 23_25. The total number of cells
and the percentage of 3β-hydroxysteroid
dehydrogenase-positive cells were determined in this Leydig cell
preparation [15]. The purity of the Leydig cells was 85%_90%.
2.3 Cell culture
Cells were maintained at 37ºC in a humidified
environment containing 95% air and 5%
CO2 for all the following experiments. In total, 5 ×
104 cells/100 µL medium (for radioimmunoassay [RIA]), 1 ×
106 cells/mL medium (for reverse transcriptase-polymerase chain
reaction [RT-PCR]) or 2.5 × 105 cells/mL medium (for
Western blot) were plated into 96 well plates or 3.5 cm
dish (Techno Plastic Products AG, Trasadingen, Switzerland), respectively.
For the dose- and time-course effects regarding
testosterone production, cells were treated with various
concentrations of GnRH-I agonist (0.01 pmol/L, 10 pmol/L,
1 nmol/L, 100 nmol/L) or GnRH-II agonist (100 pmol/L,
1 nmol/L, 10 nmol/L, 100 nmol/L) for 24 h, or cells
were treated with or without GnRH-I agonist (1 nmol/L)
or GnRH-II agonist (10 nmol/L) for various times (0, 3,
6, 12, 24 and 36 h). At the end of incubation, media
were withdrawn and testosterone levels were determined
by RIA.
In RT-PCR and Western blot experiments, cells were
treated with 1 nmol/L GnRH-I agonist, (D-Trp6)-GnRH
(Sigma-Aldrich, St. Louis, MO, USA) or 10 nmol/L GnRH-II analog, D-Arg(6)-Azagly(10)-NH2 (Peninsula
Laboratories, Belmont, CA, USA), respectively, for 12
or 24 h. At the end of incubation, the expression of
mRNA (steroidogenic acute regulatory [StAR], P450scc,
17α-hydroxylase, 3β-hydroxysteroid dehydrogenase [HSD] and
17β-HSD) and protein (StAR, P450scc and 3β-HSD) were determined.
2.4 RIA
Media from cultures with different treatments were
collected and diluted with medium to fall within the
standard curves of the respective assays. Twenty µL of
diluted sample was withdrawn into a glass tube and
100 µL each of testosterone antiserum (a generous gift
from Dr Paulus S. Wang, National Yang Ming University,
Taipei, Taiwan, China) and 3H-testosterone (70 Ci/mmol)
were added. An equilibrium reaction occurred at room
temperature for 2 h, which was stopped by putting the
tubes in ice. Charcoal was added and incubated for 15
min at 4ºC and then centrifuged at 12 000 ×
g for 10 min to centrifuge the charcoal bound with free
3H-testosterone [16]. The supernatant was poured into 2 mL of
scintillation fluid and samples were counted in a
β-counter (Beckman Coulter Instruments, Fullerton, CA, USA) for
2 min.
2.5 Isolation of RNA and RT-PCR
Total RNA was isolated with Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer's instruction. In brief, culture media was
discarded and cells were lyzed in 1 mL Trizol. Then 200
mL chloroform was added to the sample to separate it into
an aqueous phase (RNA), interphase (DNA) and organic
phase (protein). The aqueous phase was transferred to
a new vial to avoid contamination with the DNA and
protein fractions. The RNA was then precipitated by
adding 500 mL isopropyl alcohol. After centrifugation at
12 000 × g for 10 min, the supernatant was removed
and the RNA pellet was washed with 75% (v/v) ethanol.
Finally, the RNA was dissolved in 10 µL
diethylpy-rocarbonate (DEPC)-treated double distilled water and
stored at _80ºC until used. The concentration of the RNA
was determined by absorbance using 260 nm (A260).
Reverse transcription (RT) was performed in a
mixture containing 5 µmol/L random primer (primer sequence
and corresponding sequence of specific genes are listed
in Table 1), 200 mol/L deoxyribonucleotide triphosphate
(dNTP), 2U/µL moloney murine leukemia virus (MMLV)
RT together with 5 µL RNA (3 ng) as the template. The
corresponding buffer was prepared at 42ºC for 90 min
and then at 95ºC for 10 min. PCR was performed in a
mixture containing 2 µL 10 × PCR buffer, 0.4 µL 10
mmol/L dNTP, 0.4 µL 20 mmol/L specific forward and reverse
primers, 14.7 µL ddH2O, 0.1
µL 0.5 U Taq with 2 µL RT product as template for each reaction.
Thermo-controlling program consisted of 95ºC for 30 s,
55ºC for 30 s (annealing), 72ºC for 30 s and another 5 min of
elongation at 72ºC. The whole mixture was subjected to 30
cycles for amplification of L19 (internal control), StAR,
P450scc, 3β-HSD, 17α-hydroxylase and 17β-HSD. The
PCR product was then separated on a 1.5% w/v agarose
gel at 120 V for 30 min in 1 × TBE buffer (0.09 mol/L
Tris, 0.09 mol/L boric acid, 0.001 mol/L ethylene-diaminetetraacetic acid [EDTA], pH 8.0). The gel was
then stained with ethidium bromide (10%) for 10 min
and destained with double-distilled water. The mRNA of
interest in the gel was captured and quantified by using
Labwork imager system (Digital CCD Camera, Hamamtsu Photonics system, Bridgewater, NJ, USA).
The amount of L19 (405 bp) in each lane was also detected
as a control to correct the expression of StAR (451
bp), P450scc714 bp), 3β-HSD (655 bp), 17α-hydroxylase
(595 bp) and 17β-HSD (492 bp) proteins.
2.6 Immunoblot analysis
Two hundred and fifty thousand cells were cultured
in a 3.5-cm dish. After treatment, cells were rinsed
with cold phosphate buffered saline (PBS) and harvested
by addition of 30 µL lysis buffer (50 mmol/L Tris-base,
150 mmol/L NaCl, 1% [w/v] NP40, 0.1% [w/v] sodium dodecyl sulfate [SDS], 0.5% [v/v] deoxycholic acid and
1 mmol/L phenylmethanesulfonylfluoride [PMSF]). The
cell lysate was subjected to centrifugation at 12 000 ×
g for 20 min at 4ºC. The supernatant, which contained
cell protein, was collected and stored at
_20ºC until use. The protein concentration was determined by the Lowry
method [17]. Immunoblot analysis was performed as previously described [18]. Antibody against
β-actin was purchased from Cell Signaling (Beverly, MA, USA). An
antibody generated against residues 89_99 of human and
mouse StAR was a gift from Dr Jerome Strauss, III (University of Pennsylvania, Philadelphia, PA, USA) [19].
Antisera against CYP11A1 and 3β-HSD enzymes were generously provided by Dr Bon-Chu Chung (Academia
Sinica, Taipei, Taiwan, China) [20]. In brief, 20 µg
proteins was solubilized in 1 × SDS sample buffer and loaded
on a 12.5% (w/v) SDS-polyacrylamide gel
electrophoresis (PAGE) minigel (Mini-Protein II system, Bio-Rad,
Richmond, CA, USA). Electrophoresis was performed
at 100 V for 100 min using standard SDS-PAGE running
buffer. The proteins were transferred to polyvinylidene
difluoride membranes (PVDF) (Bio-Rad) at 80 mA for 1
h in transfer buffer. The PVDF membrane with transferred
protein was incubated in blocking buffer at room
temperature for 1 h, and then incubated in fresh blocking
buffer containing the primary antibody for 16_18 h at
4ºC. After washing three times with PBS containing 0.5%
[v/v] Tween-20 for 30 min, the signal was detected with
a 1 : 4 000 dilution of horseradish peroxidase-conjugated
secondary antibody (Amersham, Piscataway, NJ, USA),
and visualized with Renaissance chemiluminescence
reagent as described by the manufacturer (NEN, DuPont,
Boston, MA, USA). Proteins of interest were quantified
by a computer-assisted image analysis system (Quantity
One, Huntington Station, NY, USA). The amount of
β-actin (43 kDa) in each lane was also detected as a
control to correct the expression of StAR (30 kDa),
P450scc (51 kDa) and 3β-HSD (42 kDa) proteins.
2.7 Data analysis
All data are expressed as mean ± SEM of at least
three independent experiments. Statistically significant
differences between control and treatments were
determined by one-way analysis of variance (ANOVA) and
then the least significance difference (LSD). Statistical
significance was set at P < 0.05.
3 Results
3.1 Dose- and time-dependent effects of GnRH agonists
on testosterone production in murine Leydig cells
To determine whether GnRH can modulate
testosterone production, purified murine Leydig cells were treated
with various concentrations of GnRH-I and -II agonists
(0.01 pmol/L to 100 nmol/L) for 24 h and testosterone
production was determined by RIA. As shown in Figure
1A and 1B, significant effects of GnRH agonists on
testosterone production were observed at 1 nmol/L,
causing a ~60% increase (P < 0.05). There was no
significant difference in testosterone production by either GnRH
agonists at concentrations less than 1 nmol/L
(P > 0.05).
GnRH-I agonist at 1 nmol/L and GnRH-II agonist at
10 nmol/L were used to determine the temporal effect.
Testosterone production was significantly increased by
186% and 160% by GnRH-I and GnRH-II agonist, respectively, after
24-h treatment (Figure 1C and 1D) (P < 0.05).
These results illustrate that GnRH-I and -II agonists
significantly stimulated murine Leydig cell
steroidogenesis in a dose- and time-dependent manner.
3.2 Effects of GnRH agonists on steroidogenic enzyme
mRNA expressions in murine Leydig cells
Steroidogenic protein and/or enzymes associated
with steroidogenesis were investigated by measuring
transcript levels of mRNAs coding for StAR, P450scc,
17α-hydroxylase, 3β-HSD and 17β-HSD. Figure 2A illustrates RT-PCR results that GnRH-I agonist at 1
nmol/L and GnRH-II at 10 nmol/L induced StAR, P450scc and
3β-HSD mRNA expression after 12-h treatment. However, the
17α-hydroxylase and 17β-HSD mRNA levels were not affected by either GnRH agonist after
12- and 24-h treatments.
Figure 2B illustrates the integrated optical density
(IOD) of StAR, P450scc, 17α-hydroxylase, 3β-HSD and
17β-HSD mRNA expressions from RT-PCR results of Figure 2A after normalization for L19 mRNA
expression. The normalized results show that
GnRH-I agonist (1 nmol/L for 12 h) significantly induced 2.3-, 1.5-
and 1.8-fold increases of StAR, P450scc and 3β-HSD mRNA expression, respectively
(P < 0.05); and GnRH-II (10 nmol/L for 12
h) significantly induced 2.8-, 1.4- and 2.2-fold increases of StAR, P450scc and
3β-HSD mRNA expressions, respectively (P < 0.05).
3.3 Effects of GnRH agonists on StAR, P450scc and
3β-HSD protein expressions in murine Leydig cells
Since GnRH-I and -II agonists significantly
stimulated StAR, P450scc and 3β-HSD mRNA expressions in
murine Leydig cells, Western blotting assays were
further used to define the effects of GnRH-I and GnRH-II
agonists on protein expression of StAR, P450scc and
3β-HSD.
Figure 3A illustrates Western blotting results that
StAR and P450scc protein levels were not affected by
GnRH-I at 1 nmol/L and GnRH-II at 10 nmol/L after
12- and 24-h treatments. In contrast, 3β-HSD protein
expression was induced by both GnRH agonists after 24-h
treatment, but not 12-h treatment (Figure 3A).
Figure 3B illustrates the integrated optical density
(IOD) of StAR, P450scc and 3β-HSD protein expressions from Western blotting results of Figure 3A after
normalization with β-actin protein expression. The
normalized results show that GnRH-I agonist (1 nmol/L for
24 h) significantly induced 2.0-fold increase of
3β-HSD protein expression (P < 0.05) and GnRH-II (10 nmol/L
for 24 h) significantly induced 1.7-fold increase of
3β-HSD protein expression (P < 0.05).
These results illustrate that GnRH-I and -II agonists
only significantly stimulated 3β-HSD, but not StAR and
P450scc, protein expression in murine Leydig cells.
4 Discussion
In the present study, GnRH-I and GnRH-II agonists
significantly activated the expression of 3β-HSD enzyme
to stimulate murine Leydig cell testosterone production.
These results differ from previous reports proclaiming
no direct effect of GnRH on murine Leydig cell
steroidogenesis [14]. In fact, 5_7-week-old male B6
(C57BL/6NCrj) mice were used in the present study whereas
adult CD-1, BALB/c or NSC mice of different age and
strains were used in previous studies. Furthermore, it
has been shown that the postnatal development of Leydig
cells can be divided into progenitor Leydig cells,
immature Leydig cells and adult Leydig cells with different
testosterone-producing activity, associated with changes
in the expression levels of several different clusters of
genes, including steroidogenic enzymes [21]. In fact,
Leydig cells from immature mice possess higher steroidogenic response to trophic ligands than cells from
mature mice [21]. Thus, it is possible in the present
study that GnRH/GnRH-like receptor and 3β-HSD enzyme exist in immature murine Leydig cells, and GnRH
agonists could associate with the receptor to activate
3β-HSD enzyme and then stimulate steroidogenesis.
Many studies have demonstrated that factors from
other cell types in testis can mediate Leydig cell
functions [22, 23]. Thus, the purity of isolated Leydig cells
would influence the effect of GnRH on steroidogenesis
in mouse. The purity of isolated Leydig cells in the present
study was 85%_90%. In previous studies testicular
interstitial cells (approximately 10%_5% purity) or Leydig
cells of undefined purity were used in which other cell
types may exert paracrine interaction on Leydig cells
reducing the GnRH stimulatory effect. This might explain
the reports proclaiming no effect of GnRH on murine
Leydig cell steroidogenesis [14].
It is well established that steroidogenesis in Leydig
cells is regulated by LH to activate the G-proteins >
adenylate cyclase > protein kinase A signal transduction
pathway that phosphorylates or activates proteins, such as
StAR protein or steroidogenic enzymes. The function
of StAR protein is to transfer free cholesterol from the
cytoplasm into the inner compartment of mitochondria,
where P450scc enzyme converts cholesterol to pregnenolone [19]. Pregnenolone will then be transported to
the smooth endoplasmic reticulum for further synthesis
to testosterone by 17α-hydroxylase, 3β-HSD and 17β-HSD enzymes [24]. The function of StAR protein and
the enzymatic activity of 17α-hydroxylase have been
proposed to be the critical steps for steroidogenesis [25].
Furthermore, the expression and activity of P450scc,
17α-hydroxylase, 3β-HSD and 17β-HSD enzymes can be regulated by various factors to influence
steroidogenesis [25]. In the present study, the mRNA transcript
levels of StAR, P450scc and 3β-HSD were significantly
increased by both GnRH-I and GnRH-II agonists in
murine Leydig cells after 12-h treatment. Interestingly, only
3β-HSD protein expression was further induced by both
GnRH-I and GnRH-II agonists after 24-h treatment,
indicating that StAR and P450scc were not the major
proteins regulating GnRH-induced testosterone production
in mouse Leydig cells. Indeed, the temporal trend of
3β-HSD mRNA expression at 12 h and then protein
expression at 24 h activated by both GnRH agonists are
reasonable and consistent with other studies in which the
expression of steroidogenic enzyme takes about 12_24 h
or longer to be fully expressed [26].
Mammalian spermatogenesis and steroidogenesis are
primarily controlled by the hypothalamus and pituitary.
Additionally, various local mediators (paracrine and
autocrine factors) modulate the hormone actions both in
somatic and germ cells [24, 27]. These cell-to-cell
interactions have been shown to play important roles in
the control of testicular functions at different phases of
testicular development [24]. Increasing evidences show
that many growth factors, cytokines and secreted
proteins or peptides are involved in interactions between
Sertoli cells and Leydig cells. These Sertoli cell factors,
such as activin, inhibin, IGF-1, IGF-2, FGF, TGF-α,
TGF-β and oestradiol, might regulate the Leydig cell
functions via either stimulatory or inhibitory effects on
testosterone production [28_31]. Given that GnRH are
produced from Sertoli cells, GnRH-receptors are present on
Leydig cells [6, 7] and both forms of GnRH are able to
stimulate 3β-HSD expression and testosterone production,
it is reasonable to believe that GnRH-I and GnRH-II
should be Sertoli cell paracrine factors that mediate the
cross-compartment communication between seminiferous tubules and Leydig cells.
Taken together, GnRH directly activated murine Leydig cells to stimulate
3β-HSD expression and testosterone production, implying a role of locally produced
GnRH in the control of murine Leydig cellsteroidogen esis.
References
1. Cheng CK, Leung PC. Molecular biology of
gonadotropins-releasing hormone (GnRH)-I, GnRH-II and their receptors in
humans. Endocr Rev 2005; 26: 283_306.
2. Pierantoni R, Cobellis G, Meccariello R, Fasano S. Evolutionary
aspects of cellular communication in the vertebrate
hypothalamo_hypophysio_gonadal axis. Int Rev Cytol 2002;
218: 69_41.
3. Bahk JY, Hyun JS, Chung SH, Lee H, Kim MO, Lee BH,
et al. Stage specific identification of the expression of GnRH mRNA
and localization of the GnRH receptor in mature rat and adult
human testis. J Urol 1995; 154: 1958_61.
4. Paull WK, Turkelson CM, Thomas CR, Arimura A.
Immunohistochemical demonstration of a testicular substance
related to luteinizing hormone-releasing hormone. Science
1981; 213: 1263_4.
5. Ramakrishnappa N, Rajamahendran R, Lin YM, Leung PC.
GnRH in non-hypothalamic reproductive tissues. Anim Reprod
Sci 2005; 88: 95_113.
6. Bourne GA, Regiani S, Payne AH, Marshall JC. Testicular
GnRH receptors: characterization and localization on
interstitial tissue. J Clin Endocr Metab 1980; 51: 407_9.
7. Clayton RN, Katikineni M, Chan V, Dufau ML, Catt KJ.
Direct inhibition of testicular function by
gonadotropin-releasing hormone: mediation by specific
gonadotropin-releasing hormone receptors in interstitial cell. P Natl Acad Sci
USA 1980; 77: 4459_63.
8. Khan MA, Ferro VA, Stimson WH. Use of a highly specific
monoclonal antibody against the central variable amino acid
sequence of mammalian gonadotropin releasing hormone to
evaluate GnRH-I tissue distribution compared with GnRH-I
binding sites in adult male rats. Am J Reprod Immunol 2003;
49: 239_48.
9. Molcho J, Zakut H, Naor Z. Stimulation of prostaglandin E
and testosterone production in rat interstitial cells by a
gonadotropin-releasing hormone agonist. Endocrinology 1984;
114: 2382_7.
10. Browning JY, D'Agata R, Steinberger A, Grotjan Jr. HE,
Steinberger E. Biphasic effect of gonadotropin-releasing
hormone and its agonist analog (HOE766) on in
vitro testosterone production by purified rat Leydig cells.
Endocrinology 1983; 113: 985_91.
11. Kerr JB, Sharpe RW. Effects and interactions of LH and LHRH
agonists on testicular morphology and function in
hypophy-sectomized rats. J Reprod Fertil 1986; 76: 175_92.
12. Habert R. Effect of decapitation and chronic
in-vivo treatment with a gonadotrophin-releasing hormone agonist on testicular
steroidogenesis in the rat fetus. J Endocrinol 1992; 133:
245_51.
13. Gobbetti A, Zerani M. Mammalian GnRH involvement in
prostaglandin F2 alpha and sex steroid hormones testicular
release in two amphibian species: the anuran water frog, Rana
esculenta, and the urodele crested newt, Triturus carnifex. Gen
Comp Endocrinol 1992; 87: 240_8.
14. Wang NG, Sundaram K, Pavlou S, Rivier J, Vale W, Bardin
CW. Mice are insensitive to the antitesticular effects of
luteinizing hormone-releasing hormone agonists. Endocrinology
1983; 112: 331_5.
15. Huang BM, Stocco DM, Norman RL. The cellular mechanisms
of corticotropin-releasing hormone (CRH)-stimulated
steroidogenesis in mouse Leydig cells are similar to those for
LH. J Androl 1997; 18: 528_34.
16. Poon SL, Leu SF, Hsu HK, Liu MY, Huang BM. Regulatory
mechanism of Toona sinensis on mouse Leydig cell
steroido-genesis. Life Sci 2005; 76: 1473_87.
17. Lowry OH, Rosenborough NJ, Farr AL, Randall RJ. Protein
measurement with the folin phenol regent. J Biol Chem 1951;
193: 265_75.
18. Chen YJ, Huang YL, Huang BM. Cordyceps sinensis
mycelium activates PKA and PKC signal pathways to stimulate
steroidogenesis in MA-10 mouse Leydig tumor cells. Int J
Biochem Cell Biol 2005; 37: 214_23.
19. Stocco DM, Clark BJ. Regulation of the acute production of
steroids in steroidogenic cells. Endocr Rev 1996; 17: 221_44.
20. Guo IC, Wu LS, Lin JH, Chung BC. Differential inhibition of
progesterone synthesis in bovine luteal cells by estrogens and
androgens. Life Sci 2001; 68: 1851_65.
21. Ge RS, Dong Q, Sottas CM, Chen H, Zirkin BR, Hardy MP.
Gene expression in rat Leydig cells during development from
the progenitor to adult stage: a cluster analysis. Biol Reprod
2005; 72: 1405_15.
22. Chen L, Xin ZC, Li X, Tian L, Yuan YM, Liu G,
et al. Cox7a2 mediates steroidogenesis in TM3 mouse Leydig cells. Asian J
Androl 2006; 8: 589_94.
23. Sultana T, Svechnikov KV, Gustafsson K, Wahlgren A, Tham
E, Weber G, et al. Molecular identity, expression and functional
analysis of interleukin-1alpha and its isoforms in rat testis.
Asian J Androl 2004; 6: 149_53.
24. Saez JM. Leydig cells: endocrine, paracrine, and autocrine
regulation. Endocr Rev 1994; 15: 574_626.
25. Payne AH, Hales DB. Overview of steroidogenic enzymes in
the pathway from cholesterol to active steroid hormones.
Endocr Rev 2004; 25: 947_70.
26. Payne AH, Youngblood GL. Regulation of expression of
steroidogenic enzymes in Leydig cells. Biol Reprod 1995; 52:
217_25.
27. Reddy PR. Hormonal contraception for human males:
prospects. Asian J Androl 2000; 2: 46_50.
28. Calkins JH, Sigel MM, Nankin HR, Lin T. Interleukin-1
inhibits Leydig cell steroidogenesis in primary culture.
Endocrinology 1988; 123: 1605_10.
29. Lin T, Haskell J, Vinson N, Terracio L. Direct stimulatory
effects of insulin-like growth factor-I on Leydig cell
steroidogenesis in primary culture. Biochem. Bioph Res Co
1986; 137: 950_6.
30. Lin T, Blaisdell J, Haskell JF. Transforming growth
factor-beta inhibits Leydig cell steroidogenesis in primary culture.
Biochem. Bioph Res Co 1987; 146: 387_94.
31. Lin T, Calkins JK, Morris PL, Vale W, Bardin CW. Regulation
of Leydig cell function in primary culture by inhibin and
activin. Endocrinology 1989; 125: 2134_40.
|